Clinical Trials Browser

Advanced Solid Tumor

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

Metastatic Solid Tumors

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Advanced Solid Tumour

Pathologic Complete Response, Rectal Neoplasms

Advanced Solid Tumors

Advanced Solid Tumor

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms, Neoplasm, Residual

Lymphoma, Follicular

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of External Auditory Canal

Carcinoma, Transitional Cell

Stomach Neoplasms

Pseudomyxoma Peritonei

Locally Advanced Rectal Carcinoma

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Colorectal Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Clinical Trials

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

A Study of BG-C477 in Participants With Advanced Solid Tumors

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Pseudovax

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Endosurgery-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

FUTURE

HARBOR

NeoTISLEGA